Bridgewater Associates LP lessened its stake in Eli Lilly And Co (NYSE:LLY) by 40.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 135,421 shares of the company’s stock after selling 91,104 shares during the period. Bridgewater Associates LP’s holdings in Eli Lilly And Co were worth $14,532,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of Eli Lilly And Co by 0.4% in the third quarter. BlackRock Inc. now owns 66,925,674 shares of the company’s stock valued at $7,181,792,000 after buying an additional 280,777 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Eli Lilly And Co by 7.5% in the second quarter. Janus Henderson Group PLC now owns 10,008,768 shares of the company’s stock valued at $854,049,000 after buying an additional 700,582 shares during the period. Bank of New York Mellon Corp lifted its stake in Eli Lilly And Co by 0.3% during the third quarter. Bank of New York Mellon Corp now owns 9,501,142 shares of the company’s stock worth $1,019,568,000 after purchasing an additional 27,009 shares during the period. FMR LLC lifted its stake in Eli Lilly And Co by 526.5% during the third quarter. FMR LLC now owns 7,444,216 shares of the company’s stock worth $798,838,000 after purchasing an additional 6,255,915 shares during the period. Finally, Morgan Stanley lifted its stake in Eli Lilly And Co by 37.8% during the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock worth $381,727,000 after purchasing an additional 1,227,888 shares during the period. Institutional investors and hedge funds own 76.91% of the company’s stock.
In other news, major shareholder Eli & Co Lilly sold 4,500 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $14.44, for a total value of $64,980.00. Following the completion of the transaction, the insider now owns 3,915,654 shares in the company, valued at $56,542,043.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 14,632 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $115.91, for a total transaction of $1,695,995.12. Following the completion of the transaction, the insider now owns 119,191,172 shares of the company’s stock, valued at approximately $13,815,448,746.52. The disclosure for this sale can be found here. Insiders sold 2,127,900 shares of company stock valued at $167,037,195 in the last quarter. 0.11% of the stock is currently owned by corporate insiders.
NYSE:LLY opened at $117.00 on Friday. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $117.93. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. The company has a market capitalization of $122.38 billion, a PE ratio of 27.34, a PEG ratio of 1.80 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the company posted $1.05 earnings per share. Eli Lilly And Co’s quarterly revenue was up 7.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Eli Lilly And Co will post 5.58 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 1.92%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 52.57%.
LLY has been the subject of a number of analyst reports. ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. TheStreet cut shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Barclays raised their price target on shares of Eli Lilly And Co from $98.00 to $107.00 and gave the stock an “overweight” rating in a research note on Friday, September 7th. Cantor Fitzgerald set a $110.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research note on Monday, September 17th. Finally, JPMorgan Chase & Co. set a $117.00 price target on shares of Eli Lilly And Co and gave the stock an “overweight” rating in a research note on Wednesday, September 26th. Nine research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $111.35.
ILLEGAL ACTIVITY WARNING: “Eli Lilly And Co (LLY) Shares Sold by Bridgewater Associates LP” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/11/30/eli-lilly-and-co-lly-shares-sold-by-bridgewater-associates-lp.html.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Penny Stocks
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.